Title:
がんの再発の予測を補助する方法
Document Type and Number:
Japanese Patent JP6876294
Kind Code:
B2
Abstract:
PROBLEM TO BE SOLVED: To provide a method of supporting prediction of cancer recurrence applicable at a point of discontinuation of tyrosine kinase inhibitor or at an early stage within several months from the discontinuation.SOLUTION: The method of supporting prediction of cancer recurrence includes the steps of: measuring the number of eTreg cells in blood collected from a cancer patient; acquiring the value relevant to the number of eTreg cells based on the measurement result; classifying the patient into a recurrence low/high risk group on the basis of the value relevant to the obtained number of eTreg cells, in which the cancer patient has tyrosine kinase inhibitor administration history, and the blood is collected 20 to 50 days after stopping the administration of the tyrosine kinase inhibitor.SELECTED DRAWING: None
More Like This:
Inventors:
Hirokawa Nishikawa
Fujioka Yuki
Kobayashi Minyo
Fujioka Yuki
Kobayashi Minyo
Application Number:
JP2017059863A
Publication Date:
May 26, 2021
Filing Date:
March 24, 2017
Export Citation:
Assignee:
National Cancer Research Center
Sysmex Corporation
Sysmex Corporation
International Classes:
G01N33/48; G01N33/53
Foreign References:
| WO2016010114A1 |
Other References:
CHAUDHARY, B. et al.,Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting,Vaccines,2016年 8月 6日,4(3):28,1-25
Attorney, Agent or Firm:
Shintaro Nogawa
Shinji Kai
Yusuke Kaneko
Kiyoshi Inamoto
Shinji Kai
Yusuke Kaneko
Kiyoshi Inamoto